Factor 8 Ehl denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Extended Half-Life Factor VIII as Duplicate Therapy

A duplicate-therapy denial from UnitedHealthcare (UHC) for an extended half-life (EHL) Factor VIII product means the plan's system has identified another Factor VIII product — standard-acting or EHL — as already active on your profile. This most commonly occurs when: a previous Factor VIII prescription is still open in the claims system and has not been formally discontinued; a patient is transitioning from a standard Factor VIII product to an EHL product and both overlap during the switch; or a dispensing pharmacy submitted a claim for a second product before confirming discontinuation of the first.

## Why This Denial Is Appealable

Duplicate-therapy denials are usually administrative in nature. Two Factor VIII products are not typically co-administered; the intent is to transition, not to add. With documentation confirming the prior product has been stopped and the clinical rationale for switching to the EHL formulation, this denial should be resolved quickly.

## Federal Appeal Rights

• ERISA §503 (employer plans): Full-and-fair internal review; external review after exhaustion.
• ACA §2719 (individual/small-group plans): External IRO review. The window to request external review is typically approximately four months from the final internal denial — verify the exact date on your denial letter.
• Expedited review: If factor shortage would put you at clinical risk, request expedited processing.

## Appeal Process and Timeline

1. Contact UHC's pharmacy benefit team first — confirm whether the prior Factor VIII claim is still showing as active and request that it be closed. 2. Have the prescribing pharmacy submit a discontinuation record for the prior product. 3. File a formal internal appeal if the administrative correction does not resolve the denial. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Discontinuation record: Chart note or pharmacy record confirming the prior Factor VIII product was stopped, with the date.
• Prescription for the EHL product: Confirming this is a replacement, not an addition.
• Prescriber letter: Brief letter from the hematologist explaining the transition from the prior product to the EHL formulation and confirming they are not intended to be used simultaneously.
• Clinical rationale for switching: Documentation of the reason for the switch — for example, moving from standard Factor VIII to EHL to reduce infusion frequency.

## Criteria-Mapping Structure

For a duplicate-therapy appeal, the exhibit package is straightforward:

| Denial Basis | Rebuttal Evidence | |---|---| | Second Factor VIII product on file | Discontinuation record for prior product | | Overlap in active claims | Pharmacy switch documentation | | Medical rationale for transition | Prescriber transition letter |

This type of denial frequently resolves at the administrative or Level 1 internal appeal stage once the transition documentation is received.